AstraZeneca Pharma receives marketing approval for Benralizumab in India
Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
The receipt of this permission paves way for the marketing of Benralizumab 30 mg/ml Solution for Injection (Brand name: Fasenra) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content